Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion on March 11, 2024. As of May 16, 2024, the agreement was revised and under the revised terms Hyundai Bioscience will now acquire 30.33% stake, CnPharm will acquire 2.89% stake and Yeonjin Kim will acquire 1.69% stake in ADM Korea. Transaction is expected to May 20, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,845 KRW | +2.71% | -6.57% | +46.80% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
18,700 KRW | +0.11% | -4.40% | 541M | ||
3,540 KRW | -0.42% | -1.39% | 82.55M | ||
2,845 KRW | +2.71% | -6.57% | 42.6M | ||
1st Jan change | Capi. | |
---|---|---|
+46.80% | 42.6M | |
+40.80% | 55.66B | |
-8.05% | 38.98B | |
+35.79% | 38.8B | |
-8.98% | 27.32B | |
+10.69% | 26.29B | |
-16.21% | 20.25B | |
+31.00% | 12.76B | |
+28.51% | 12.18B | |
-1.67% | 12.12B |
- Stock Market
- Equities
- A187660 Stock
- News ADM Korea Inc.
- Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.